DME (psychedelic)

DME
Names
Preferred IUPAC name
2-Amino-1-(3,4-dimethoxyphenyl)ethan-1-ol
Other names
3,4-Dimethoxy-beta-hydroxyphenethylamine
3,4-Dimethoxy-1-ethyl-(beta-hydroxy)amine
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C10H15NO3/c1-13-9-4-3-7(8(12)6-11)5-10(9)14-2/h3-5,8,12H,6,11H2,1-2H3 checkY
    Key: WIUFFBGZBFVVDL-UHFFFAOYSA-N checkY
  • InChI=1/C10H15NO3/c1-13-9-4-3-7(8(12)6-11)5-10(9)14-2/h3-5,8,12H,6,11H2,1-2H3
    Key: WIUFFBGZBFVVDL-UHFFFAOYAL
  • COc1cc(ccc1OC)C(O)CN
  • O(c1ccc(cc1OC)C(O)CN)C
Properties
C10H15NO3
Molar mass 197.234 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

DME (3,4-dimethoxy-beta-hydroxyphenethylamine) is a lesser-known psychedelic drug. It is the beta-hydroxy derivative of 3,4-dimethoxyphenethylamine. DME was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 115 mg, and the duration unknown. DME produces few to no effects.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of DME.

Legality

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

References

  1. ^ DME Entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.
Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.